Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anti-RSV therapeutics - Medivir AB

Drug Profile

Research programme: anti-RSV therapeutics - Medivir AB

Alternative Names: Anti-RSV therapeutics research programme - Boehringer Ingelheim; MIV 323; RSV fusion protein inhibitor - Medivir AB

Latest Information Update: 28 Dec 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim (Canada)
  • Developer Medivir AB
  • Class Small molecules
  • Mechanism of Action DNA-directed RNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Respiratory syncytial virus infections

Most Recent Events

  • 28 Dec 2018 No recent reports of development identified for preclinical development in Respiratory-syncytial-virus-infections in Sweden (PO)
  • 21 Dec 2016 Research programme: anti-RSV therapeutics - Medivir AB is available for licensing as of 14 Dec 2016. http://www.medivir.se/v5/en/
  • 14 Dec 2016 Preclinical development is ongoing in Sweden
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top